ASCO 2021: Pembrolizumab shows promise for adjuvant treatment of renal cell carcinoma

Written by | 18 Jun 2021

Immunotherapy with pembrolizumab after surgery significantly improves disease-free survival among patients with the most prevalent form of  kidney cancer, clear-cell renal carcinoma. Researchers reported this finding on June […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.